Investors & Media

News

October 22, 2020

Sage Therapeutics Announces Chief Executive Jeff Jonas to Undergo Scheduled Medical Procedure

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 22, 2020-- Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that Jeff Jonas, M.D., chief executive officer, will undergo a scheduled surgical procedure today. The Company anticipates he will make a full recovery and return to his role full-time in December 2020. While Dr. Jonas is recuperating, he will be available as needed, and during this time, the Sage leadership team will direct business operations. In addition, Sage’s experienced Board of Directors will continue to serve as a resource.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

Investor Contact
Jeff Boyle
617-949-4256
Jeff.Boyle@sagerx.com

Media Contact
Maureen L. Suda
617-949-4289
maureen.suda@sagerx.com

Source: Sage Therapeutics, Inc.